Equities

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Actions
  • Price (EUR)32.14
  • Today's Change0.00 / 0.00%
  • Shares traded109.00
  • 1 Year change-28.59%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue3977567
OPERATING EXPENSES
Cost of revenue total595.645.20
Selling, general and admin. expenses, total501277177
Depreciation/amortization------
Unusual expense(income)033101
Other operating expenses, total------
Total operating expense914703703
Operating income(517)(628)(637)
Other, net(0.73)(0.29)1.36
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes(526)(652)(746)
Provision for income taxes2.130.670.35
Net income after taxes(529)(652)(746)
Minority interest------
Net income before extra. Items(529)(652)(746)
Total extraordinary items------
Net income(529)(652)(746)
Inc.avail. to common excl. extra. Items(529)(652)(746)
Inc.avail. to common incl. extra. Items(529)(652)(746)
EPS RECONCILIATION
Basic/primary weighted average shares11910684
Basic/primary eps excl. extra items(4.45)(6.15)(8.84)
Basic/primary eps incl. extra items(4.45)(6.15)(8.84)
Dilution adjustment------
Diluted weighted average shares11910684
Diluted eps excl. extra items(4.45)(6.15)(8.84)
Diluted eps incl. extra items(4.45)(6.15)(8.84)
COMMON STOCK DIVIDENDS
DPS - common stock primary issue------
Gross dividend - common stock000
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental303313
SUPPLEMENTAL INCOME
Depreciation, supplemental1.781.551.38
Total special items033101
NORMALISED INCOME
Normalized income before taxes(526)(619)(645)
Effect of special items on income taxes01235
Income tax excluding impact of special items2.131236
Normalized income after tax(529)(631)(681)
Normalized income avail. to common(529)(631)(681)
Basic normalized EPS(4.45)(5.94)(8.07)
Diluted normalized EPS(4.45)(5.94)(8.07)
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.